HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

LENZ Therapeutics, Inc.

LENZ Therapeutics, Inc.

LENZ

0.00

HC Wainwright & Co. analyst Matthew Caufield reiterates LENZ Therapeutics (NASDAQ: LENZ) with a Buy and maintains $38 price target.